Cargando…

Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study

The aim of this study was to test whether a low dose of interferon-α-2b (IFN-α2b) enhances the clinical outcome of docetaxel (DXT) in patients with castration-resistant prostate cancer (CRPC). A prospective controlled trial of 40 CRPC patients receiving 5 mg of prednisone twice daily was conducted,...

Descripción completa

Detalles Bibliográficos
Autores principales:	LI, YUN-FEI, WANG, QIN-ZHANG, ZHANG, TAO-TAO, LI, LEI, WANG, JIANG-PING, DING, GUO-FU, HE, DA-LIN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861530/ https://www.ncbi.nlm.nih.gov/pubmed/24348833 http://dx.doi.org/10.3892/ol.2013.1653

Ejemplares similares

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance
por: Cai, Xiang, et al.
Publicado: (2023)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
por: Kim, Hae Su, et al.
Publicado: (2017)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with Castration-Resistant Prostate Cancer
por: Min, Byung-Dal, et al.
Publicado: (2012)

Relationships of body composition and adipocytokines with outcomes in metastatic castration-resistant prostate cancer patients receiving docetaxel chemotherapy
por: Li, Jun-Hong, et al.
Publicado: (2023)

Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy
por: Yu, Yang, et al.
Publicado: (2021)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells
por: Tanaudommongkon, Irin, et al.
Publicado: (2020)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
por: Isaksson, Jenny, et al.
Publicado: (2021)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells
por: Li, Senmao, et al.
Publicado: (2021)

Synergistic Antitumor Activities of Docetaxel and Octreotide Associated with Apoptotic-Upregulation in Castration-Resistant Prostate Cancer
por: Zhu, Sha, et al.
Publicado: (2014)

Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan
por: Chiang, Ping-Chia, et al.
Publicado: (2023)

External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
por: Nakano, Kazuhiko, et al.
Publicado: (2014)

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
por: Lin, H-M, et al.
Publicado: (2014)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
por: Ning, Wei, et al.
Publicado: (2023)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
por: Davis, Keith L., et al.
Publicado: (2015)

Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics
por: Deris, Atefeh, et al.
Publicado: (2023)

Initial treatment outcome and feasibility of low-dose cabazitaxel against docetaxel- and castration-resistant prostate cancer in a Japanese hospital
por: Chaya, Ryosuke, et al.
Publicado: (2020)

A multicenter observational study of the real‐world use of docetaxel for metastatic castration‐resistant prostate cancer in China
por: He, Dalin, et al.
Publicado: (2019)

Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
por: Maj-Hes, Agnieszka, et al.
Publicado: (2021)

Prospective Evaluation of Low-Dose Ketoconazole Plus Hydrocortisone (HC) in Docetaxel Pre-treated Castration-Resistant Prostate Cancer (CRPC) Patients
por: Lo, Ernest N., et al.
Publicado: (2015)

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
por: Sartor, A Oliver
Publicado: (2011)

Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy
por: Ohtaka, Ayako, et al.
Publicado: (2019)

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
por: Byeon, Seonggyu, et al.
Publicado: (2020)

Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
por: Halabi, Susan, et al.
Publicado: (2020)

Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer
por: Mao, Lijun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1mmci2iec9jef95o922ajvhb5e